Академический Документы
Профессиональный Документы
Культура Документы
DEFINITION Neuropathy is defined as a disease or i j injury of f th the peripheral i h l sensory, motor, t or autonomic nerves. Can be : - pure motor - pure sensory - mixed sensorimotor - autonomic t i
Category
Usually categorized separately : N Neuronopathy th : selective l ti i injury j to t the th cell body of the axon Radiculopathy : selective injury to the nerve roots distal to their origin Plexopathy : injury to the brachial or p lumbosacral plexus
CLASSIFICATION
1. BASED ON THE ONSET OF NEUROPATHY: ACUTE NEUROPATHY eg. : ACUTE IDIOPATHIC POLYNEUROPATHY CHRONIC NEUROPTHY
eg.
2. BASED ON SEVERITY
1. MILD NEUROPATHY : SENSORY ONLY 2. MODERATE NEUROPATHY : SENSORY MOTOR SENSORY, MOTOR, AND DECREASE OF TENDON REFLEXES 3. SEVERE NEUROPATHY : SENSORY, MOTOR, DECREASE OF TENDON REFLEXES, MUSCLE ATROPHY
3.
ETIOLOGY
1. IDIOPATHIC INFLAMMATORY NEUROPATHIES
ACUTE IDIOPATHIC POLYNEUROPATHY (GUILLAIN BARRE SYNDROME) - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
2. METABOLIC AND NUTRITIONAL NEUROPATHIES - DIABETES, , HYPOTHYROIDI, , ACROMEGALY - UREMIA - LIVER DISEASES - VIT B1, OR VIT B12 DEFICIENCY
ETIOLOGY
3. INFECTIVE AND GRANULOMATOUS NEUROPATHIES: AIDS, LEPROSY. DIPHTHERY, SARCOIDOSIS 4. VASCULITIS NEUROPATHIES: - POLYARTERITIS NODOSA - RHEUMATOID ARTHRITIS - SYSTEMIC LUPUS ERYTHEMATOSUS
ETIOLOGY
5. NEOPLASTIC AND PARAPROTEINEMIC NEUROPATHIES: - COMPRESSION AND IRITATION BY TUMOR - PARANEOPLASTIC SYNDROME - PARAPROTEINEMIAS - AMYLOIDOSIS
ETIOLOGY
6. DRUGS INDUCED AND TOXIC NEUROPATHIES - DAPSONE, ISONIAZIDE, PHENYTOIN, PIRIDOXYNE, VINCRISTIN, HIDRALAZINE. - ALCOHOL - TOXINS : ORGANOPHOSPHAT ARSENIC LEAD THALIUM GOLD
ETIOLOGY (cont.d)
7. HEREDITARY NEUROPATHIES - IDIOPATHIC
HEREDITARY MOTOR AND SENSORY NEUROPATHIES HEREDITARY SENSORY NEUROPATHIES FAMILIAL AMYLOIDOSIS
- METABOLIC
PORPHYRIA METACHROMATIC LEUCODYSTROPHY ABETALIPOPROTEINEMIA
ETIOLOGY
8. ENTRAPMENT NEUROPATHIES - UPPER LIMBS
MEDIAN NERVE (CARPAL TUNNEL SYNDROME) ULNAR NERVE RADIAL NERVE
- LOWER LIMBS
PERONEAL NERVE FEMORAL NERVE OBTURATOR NERVE
PATHOGENESIS
Can be divided into 4 major categories : 1. Neuronal degeneration : results from damage to the motor or sensory nerve cell ll bodies, b di with i h subsequent b degeneration d i 2. Wallerian degeneration : results from damage to the axon at a specific point below the cell body, with degeneration distal t th to the i injury. j 3. Axonal degeneration : results from diffuse axonal damage. The distal portion undergoes the earliest and most severe change h followed f ll d by b gradual d l proximal i l ascent t with ith continued ti d injury (dying back phenomenon) 4. Segmental demyelination : results from injury to the myelin sheath h th without ith t injury i j to t the th axon
PATHOPHYSIOLOGY
1 NEUROPRAXIS : 1.
- the mildest form - conduction disruption only - intact nerve continuity y - recovery in minutes or weeks
PATHOPHYSIOLOGY
2. AXONOTMESIS: - AXONAL DAMAGE FOLLOWED BY DEGENERATION - ENDONEURAL SHEATH REMAINS INTACT - POSSIBLE REGENERATION
PATHOPHYSIOLOGY
3. NEUROTMESIS: - PARTIAL OR TOTAL NERVE DAMAGE - SURGICAL INTERVENTION IS NEEDED - 50% RECOVER
CLINICAL SYMPTOMS
1. SENSORY SYMPTOMS :
Involvement of sensory axons produces impairment of sensation with dysesthesias or paresthesias.
CLINICAL SYMPTOMS
2. MOTOR SYMPTOMS :
Involvement of motor axons produces muscle wasting and weakness followed by atrophy and fasciculations
- LMN TYPE MUSCLE WEAKNESS - FOOT DROP - WRIST DROP
CLINICAL SYMPTOMS
3. CHANGE OF TENDON REFLEXES The tendon reflexes supplied by the
affected nerve are depressed or absent.
CLINICAL SYMPTOMS
4. AUTONOMIC :
Involvement of axons supplying autonomic function produces loss of sweating, alteration in bladder fuction, constipation, and impotence in male
DIAGNOSIS
1. 2. 3. 4. 5 5. 6. CLINICAL SYMPTOMS AND SIGNS LABORATORY STUDIES CHEST X-RAY LP ECG BIOPSY : sural nerve or radial cutaneus nerve
DIABETIC NEUROPATHY
Neuropati diabetik : adanya gejala dan atau tanda disfungsi saraf perifer pd orang dgn diabetes setelah dieksklusikan penyebab lain. lain Prevalence : 10 - 20 % (symptomatic)
Diabetic Neuropathy : 50% of diabetic patients type 1 than type 2 the most common : chronic sensorimotor 50% asymptomatic 10-20% needs specific treatment
DIAGNOSIS
THERAPY
Intensive diabetic therapy M i t i ideal Maintain id l body b d weight i ht Adjuvant analgetics : TCA antidepressants carbamazepine gabapentin i t intravenous lid lidocaine, i etc t
Adjuvant Analgetics
Etiology
1. Hereditary : HMSN type III 2. Traumatic : dislocation, fracture, hematoma, wrist sprain 3. Infection : tenosynovitis, tbc, sarcoidosis 4. Metabolic : amyloidosis, gout 5 Endocrine : acromegaly 5. acromegaly, DM DM, hypothyroidism hypothyroidism, pregnancy 6. Neoplastic : ganglion cysts, lipoma , myeloma 7 Collagen vascular diseases : RA, 7. RA polymyalgia rheumatica, SLE 8. Degenerative disease : OA 9. Iatrogenic : radial artery puncture, shunt for dialysis, anticoagulant therapy
Clinical Symptoms The earliest symptoms : numbness and paresthesias in the sensory distribution of the median nerve in the hand (thumb, ( , index, , middle and lateral half of the ring finger) Later on : p pain, , worst at night g Late : inability to screw bottle caps or grip g p properly p p y
Therapy
Identified causes should be treated Corticosteroid injection around the median nerve in the carpal tunnel. Surgical division of the transverse ligament (flexor retinaculum) Endoscopic carpal tunnel release
Rapidly progressive paralysis, often ascending di Areflexia Increased CSF protein without increased cell count (albuminocytologic dissociation) Evidence of demyelination on nerve conduction d ti studies t di ( (may b be d delayed) l d) A neurologic emergency that may rapidly progress to respiratory compromise
GBS : DIAGNOSTIC STUDIES Imaging studies of the spinal cord to rule out myelopathic disease. disease LP (after spinal cord disease excluded) Evaluation for infection ECG Chest radiographs EMG/NCV
THERAPY
PLASMAPHARESIS (5-6 exchanges over 1- 2 weeks) ) or IMMUNOGLOBULIN IV (0,4 g/kg/day for 5 days) Equally effective when given within the first 2 weeks after onset Combination of both no additional benefit RCTs on oral or IV corticosteroid failed to show benefit